Cargando…
The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residua...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762036/ https://www.ncbi.nlm.nih.gov/pubmed/33291846 http://dx.doi.org/10.3390/jcm9123941 |
_version_ | 1783627709068345344 |
---|---|
author | Vernero, Marta De Blasio, Federico Ribaldone, Davide Giuseppe Bugianesi, Elisabetta Pellicano, Rinaldo Saracco, Giorgio Maria Astegiano, Marco Caviglia, Gian Paolo |
author_facet | Vernero, Marta De Blasio, Federico Ribaldone, Davide Giuseppe Bugianesi, Elisabetta Pellicano, Rinaldo Saracco, Giorgio Maria Astegiano, Marco Caviglia, Gian Paolo |
author_sort | Vernero, Marta |
collection | PubMed |
description | Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residual symptoms and inflammatory markers in a population of patients with ulcerative colitis (UC). Forty-two patients with UC in clinical remission were enrolled in the study. Three patients were lost to follow up; 39 patients (18 treated with BLM add-on therapy and 21 with standard mesalamine only) that reached 12 months of follow up were included in the final analysis. Therapeutic success (defined as Mayo partial score ≤ 2 and faecal calprotectin (FC) < 250 µg/g at 12 months of follow up) was achieved in 25 patients (64.1%); 15/18 (83.3%) in BLM group and 10/21 (47.6%) in control group (p = 0.022). Consistently, 13/18 patients (72.2%) receiving BLM improved residual symptoms compared to 5/21 patients (23.8%) in control group (p = 0.003). FC values significantly diminished from the baseline to the end of follow up in patients that received BLM, while FC values remained almost stable in the control group. In conclusion, oral BLM supplementation appears to be a valid add-on therapy in order to maintain remission in patients with UC. Further randomized, placebo-controlled, double-blind clinical trials are needed to validate our results on a larger population or cohort of patients. |
format | Online Article Text |
id | pubmed-7762036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77620362020-12-26 The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study Vernero, Marta De Blasio, Federico Ribaldone, Davide Giuseppe Bugianesi, Elisabetta Pellicano, Rinaldo Saracco, Giorgio Maria Astegiano, Marco Caviglia, Gian Paolo J Clin Med Article Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residual symptoms and inflammatory markers in a population of patients with ulcerative colitis (UC). Forty-two patients with UC in clinical remission were enrolled in the study. Three patients were lost to follow up; 39 patients (18 treated with BLM add-on therapy and 21 with standard mesalamine only) that reached 12 months of follow up were included in the final analysis. Therapeutic success (defined as Mayo partial score ≤ 2 and faecal calprotectin (FC) < 250 µg/g at 12 months of follow up) was achieved in 25 patients (64.1%); 15/18 (83.3%) in BLM group and 10/21 (47.6%) in control group (p = 0.022). Consistently, 13/18 patients (72.2%) receiving BLM improved residual symptoms compared to 5/21 patients (23.8%) in control group (p = 0.003). FC values significantly diminished from the baseline to the end of follow up in patients that received BLM, while FC values remained almost stable in the control group. In conclusion, oral BLM supplementation appears to be a valid add-on therapy in order to maintain remission in patients with UC. Further randomized, placebo-controlled, double-blind clinical trials are needed to validate our results on a larger population or cohort of patients. MDPI 2020-12-04 /pmc/articles/PMC7762036/ /pubmed/33291846 http://dx.doi.org/10.3390/jcm9123941 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vernero, Marta De Blasio, Federico Ribaldone, Davide Giuseppe Bugianesi, Elisabetta Pellicano, Rinaldo Saracco, Giorgio Maria Astegiano, Marco Caviglia, Gian Paolo The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study |
title | The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study |
title_full | The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study |
title_fullStr | The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study |
title_full_unstemmed | The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study |
title_short | The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study |
title_sort | usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762036/ https://www.ncbi.nlm.nih.gov/pubmed/33291846 http://dx.doi.org/10.3390/jcm9123941 |
work_keys_str_mv | AT verneromarta theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT deblasiofederico theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT ribaldonedavidegiuseppe theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT bugianesielisabetta theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT pellicanorinaldo theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT saraccogiorgiomaria theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT astegianomarco theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT cavigliagianpaolo theusefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT verneromarta usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT deblasiofederico usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT ribaldonedavidegiuseppe usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT bugianesielisabetta usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT pellicanorinaldo usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT saraccogiorgiomaria usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT astegianomarco usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy AT cavigliagianpaolo usefulnessofmicroencapsulatedsodiumbutyrateaddontherapyinmaintainingremissioninpatientswithulcerativecolitisaprospectiveobservationalstudy |